

**CORDLIFE GROUP LIMITED**  
(Company Registration No.: 200102883E)  
(Incorporated in the Republic of Singapore)

---

**INCREASE IN SHAREHOLDING IN STEMLIFE BERHAD**

---

The Board of Directors ("**Board**") of Cordlife Group Limited (the "**Company**") refers to the Company's announcements on 10 November 2016 and 17 November 2016 (collectively, the "**VGO Announcements**") that the Company had, through Maybank Investment Bank Berhad, served a notice and supplemental notice respectively on the board of directors of StemLife Berhad ("**StemLife**"), to notify it of the Company's intention to make a voluntary take-over offer to acquire all the remaining shares in the share capital of StemLife not already owned by the Company (the "**Offer Shares**") (the "**VGO**").

Further to the VGO Announcements, the Board wishes to announce that, as at 5.30 p.m. today, the Company has received valid acceptances in respect of 140,700 Offer Shares (the "**Acceptances**"). The VGO is open for acceptances until 5.00 p.m. (Malaysian time) on 31 January 2017.

The Company has today also acquired 44,000 shares, representing approximately 0.01% of the issued and paid-up capital of StemLife (the "**Acquisition**"). The aggregate cash consideration paid for the StemLife shares which were purchased on the Bursa Malaysia market is RM25,300 (approximately S\$8,102), being an average of approximately RM0.575 per StemLife share.

The Acquisition is not expected to have any material impact on the net assets per share or earnings per share of the Company for the current financial year ending 30 June 2017.

In addition, further to the Company's announcement on 14 December 2016 regarding the Notice (as defined therein), the Company is required to acquire 16,500 Offer Shares, pursuant to Subsection 223(1) of the Capital Markets and Services Act, 2007 of Malaysia (the "**Compulsory Acquisition**").

Prior to the date of this Announcement, the Company held and had previously acquired an aggregate of 243,859,279 StemLife shares. As a result of the Acceptances, Acquisition and Compulsory Acquisition, as at the date of this Announcement, the Company owns or has agreed to acquire an aggregate of 244,060,479 StemLife shares, representing approximately 98.61% of the issued and paid-up capital of StemLife.

Dr Ho Choon Hou, who is a director of the Company, is also a director of StemLife. Save for the foregoing, none of the directors and controlling shareholders of the Company has any interest, direct or indirect, in the Acquisition.

By Order of the Board  
**CORDLIFE GROUP LIMITED**

Dr. Wong Chiang Yin  
Executive Director and Group Chief Executive Officer  
26 January 2017